At the parenteral dosage form level, a liquid inactivated whole-cell Bordetella antigen concentrate is standardised against a lot-specific opacity reference and released under 9 CFR 113.64 purity criteria before downstream blending. The target segment is the porcine atrophic rhinitis bacterin market, where the API is compounded with aluminium hydroxide adjuvant in jacketed stainless steel vessels of 500 L to 1,000 L working volume. The addition sequence is not reversible: the adjuvant gel is hydrated and pH-adjusted to 6.8–7.2 before the antigen is introduced through a sidearm at 2–8 °C. A bottom-mounted impeller operating at 80–120 rpm keeps the flocculated suspension homogeneous without generating a free vortex. Rotor/stator high-shear mixing above 3,000 rpm is deliberately avoided because it can strip fimbrial haemagglutinin structures from the bacterial surface and reduce potency in the final potency test. The finished suspension is filled into 100 mL and 250 mL polypropylene or high-density polyethylene bottles on a peristaltic or rotary piston line; in-process checks include bulk pH, settleability, and appearance. Final release relies on sterility by Ph. Eur. 2.6.1, bacterial purity by 9 CFR 113.64, and lot identity against a reference serum panel. For companion animal injectable presentations, the same liquid concentrate can be diluted into reduced-adjuvant formulations for subcutaneous administration, but published comparative data for injection-site reaction rates across canine breeds remains limited. Preservative incompatibility must be controlled: benzalkonium chloride and high-concentration phenolics destabilise the aluminium gel.

Another downstream route in the injectables segment uses a lyophilised live modified-live API for multi-dose vials and single-dose vaccination kits. The dry cake is aseptically filled as a solution before freeze-drying; therefore the fill line operates inside an ISO 14644-1 class 5 restricted-access barrier system. Residual moisture after lyophilisation is measured by Karl Fischer coulometric titration under Ph. Eur. 2.5.32; acceptance is set to prevent cake collapse and preserve antigen conformation during storage at 2–8 °C. The product is backfilled with nitrogen to reduce oxidative damage. Reconstitution time is not merely a user convenience issue: slow wetting of the cake leads to microfoam that increases droplet heterogeneity if the solution is subsequently used with a spray adapter. Freeze-drying microscopy is used to determine the glass transition temperature of the specific excipient matrix, but published data for this Bordetella antigen-configured cake is limited. Each new lyophilisation cycle must therefore be bracketed with analytical temperature mapping across all shelves.

What limits lyophilised cake reconstitution in multi-dose injection kits?

Reconstitution failure is most frequently caused by incomplete primary drying, ice crystal collapse, or moisture ingress through elastomer closures during storage. The lyophilised Bordetella vaccine API is typically formulated with sucrose, trehalose, or glycine as a cryoprotectant matrix. The cake mass is fixed by dose volume, but the reconstitution diluent must be matched to the matrix tonicity. If the API is rehydrated with a hypotonic diluent below 250 mOsm/kg, rapid osmotic shock can rupture bacterial cells. If a hypertonic diluent above 350 mOsm/kg is used, cellular dehydration reduces viable counts. Production lines therefore use pre-filled diluent syringes with osmolality controlled by freezing point depression. The filled vial is backfilled with nitrogen and sealed with chlorobutyl elastomer closures tested for moisture vapour transmission. Seal integrity is verified by dye ingress or vacuum decay. The reconstituted suspension is not terminally filtered; it is aspirated through a 21-gauge needle without clogging when the cake is properly lyophilised. Poorly lyophilised cake produces a gritty suspension that blocks needles and creates dose non-uniformity under Ph. Eur. 2.9.5 and USP <905>.

The boundary for this dosage form is strict: live Bordetella antigen cannot be autoclaved, cannot be exposed to ethylene oxide, and cannot be irradiated at sterilising doses without losing viability. The lyophiliser shelf-loading pattern must avoid edge vials with higher heat transfer. In freeze-drying, the primary drying pressure and shelf temperature are controlled to avoid product temperature above the collapse temperature. Published data for the specific collapse temperature of Bordetella vaccine cake is limited; therefore each formulation requires freeze-drying microscopy and differential scanning calorimetry. In-line near-infrared monitoring of residual moisture after unloading improves batch consistency. A small number of facilities operate fully automated loading and unloading under positive pressure nitrogen to protect the API from ambient humidity above 5% RH.

When oral solid dosage carriers are blended with lyophilized antigen

Oral tablet and capsule development for canine kennel cough uses the lyophilised Bordetella API in dry-blend form. The blend room humidity is held below 25% RH because the dried antigen is hygroscopic. Above this threshold the material becomes cohesive, hopper flow ceases, and die filling on the rotary press becomes erratic. Flowability is measured by Ph. Eur. 2.9.36 compressibility index and Hausner ratio before compression. Direct compression is preferred over wet granulation because wet massing introduces water and shear that degrade the antigen. The compression force on a rotary tablet press is established by dose-ranging studies; published data for this specific Bordetella antigen formulation is limited. The press is operated with low force-feeder paddle speed and reduced precompression force to limit localised heat accumulation. Tablet hardness, friability, and disintegration are controlled under Ph. Eur. 2.9.1 and Ph. Eur. 2.9.7. For capsule presentations, tamping-pin filling is preferred over dosator-type filling because the dosator bowl densifies the powder bed and can cause frictional heating in the powder column. Capsule weight variation is checked under Ph. Eur. 2.9.5 or USP <905>. The filled solid doses are packaged in aluminium-aluminium blisters with nitrogen purging. Thermoforming temperatures above 60 °C must not contact the dosage form. Any claim that a lyophilised vaccine remains fully potent after tableting must be confirmed against the original liquid reference in a parallel in vivo potency trial; surrogate tests alone are insufficient.

Incompatibility boundaries include sustained-release excipients that create low-pH microenvironments and tonicity-adjusting salts above 0.9% w/v in rehydrated cores. If the oral dosage form is intended for mucosal release rather than systemic delivery, disintegration time in simulated saliva under Ph. Eur. 2.9.1 is a more relevant in-process control than gastric acid resistance. Published production-scale data for such formulations is limited to a small number of veterinary vaccine producers, and transfer from laboratory scale to a 500 kg bin blender requires re-validation of blend uniformity. The drying capacity of the excipient system must be sufficient to keep the local moisture level below the antigen denaturation threshold for the entire compression run, including the final tablets discharged at the end of the batch.

Intranasal solution viscosity and turbinate-associated lymphoid tissue deposition

The solution dosage form for canine and feline Bordetella bronchiseptica vaccination is manufactured as a single-dose or low-volume multi-dose liquid containing live attenuated bacteria. The process stream is aseptic and non-terminal: terminal heat sterilisation is incompatible with live organisms. The solution is compounded at 2–8 °C with a viscosity target that ensures reproducible spray formation from a single-use cannula. Dose volumes of 0.2 mL to 0.5 mL per nostril are typical in commercial presentations. Rotational viscosity is measured under Ph. Eur. 2.2.10, and droplet-size distribution is verified by laser diffraction under ISO 13320-1. No antimicrobial preservative is added because benzalkonium chloride and thimerosal can reduce viability; the vial must be used immediately after opening. The fill line uses peristaltic pumps with 0.22 μm sterilising-grade filters for the diluent stream; the antigen is not filtered if it exceeds the filter retention threshold for particulate bacteria.

Spray pattern testing is conducted with a mechanical actuation fixture that simulates the canine nostril angle. A uniform plume with a geometric mean droplet size in the range specified by the device qualification is required. Buffer salts and stabilisers are selected to maintain osmolarity near 300 mOsm/kg and pH between 7.0 and 7.4. Published data for the exact viscosity range of Bordetella intranasal solutions is limited because commercial manufacturers treat formulation as proprietary. Failure modes observed on production lines include nozzle clogging from aggregated antigen, uneven fill volumes caused by gas evolution from stabiliser degradation, and viability loss during extended hold times. The solution is filled in single-dose vials or pre-filled cannula devices in a grade A environment. The filled device is not subjected to terminal sterilisation; container closure integrity is maintained by the device design and verified by vacuum leak testing. Stability is assessed according to VICH GL1 with real-time data at 2–8 °C and accelerated conditions not exceeding 25 °C for brief distribution excursions.

Granulated and powder premix demand is driven by integrated swine operations that require mass oral administration without individual animal handling. A lyophilised or spray-dried Bordetella antigen is first blended with a protective diluent such as mannitol, skim milk powder, or maltodextrin; the mixture is then granulated on a fluid-bed system. Inlet air temperature is set below 30 °C in qualification batches. Published data for the specific heat liability of Bordetella vaccine API in fluid-bed granulation is limited, so each lot is spiked with a viability indicator and sampled during drying. The granules are collected at 2–8 °C and immediately sized through a 1.0 mm screen. Final premix dilution with ground corn cob or dextrose carrier is performed in a horizontal ribbon blender at 20–30 rpm. Potency and homogeneity are verified using 9 CFR 113.64 and Ph. Eur. 2.9.36 flow properties. The premix is not pelletised; it is applied post-pelleting via a microdosing cabinet or top-dressed onto the feed. Co-administration with ionophore anticoccidials or high-dose oral antibiotics requires a washout period before vaccination because live bacterial viability may be suppressed.

The premix boundary is strict: free water contact, pH shifts below 6.0, and conditioning temperatures above 65 °C are all known to degrade live bacterial antigen. Several integrators require split-batch testing for antigen uniformity across the first, middle, and last discharge from the mixer. Published commercial data for Bordetella premix uniformity is limited, but the same sampling plan is standard for live bacterial feed additives under veterinary oversight. The finished premix is packaged in moisture-barrier woven bags with an internal polyethylene liner and stored at 2–8 °C. The product must not be stacked in direct sunlight or stored near heat sources. The microdosing system must be calibrated gravimetrically before each batch and at least once per shift to ensure dose accuracy under the approved veterinary prescription.

Aseptic powder fill lines for turkey hatchery spray share lyophilization constraints

In turkey production, Bordetella avium vaccination is applied as a hatchery spray solution prepared from a freeze-dried or spray-dried powder. The powder is filled under low humidity into moisture-barrier pouches or aluminium-sealed vials. Reconstitution takes place in cold distilled water or a designated diluent immediately before cabinet spray application. The spray cabinet nozzles produce a droplet cloud that must contact the poults’ upper respiratory mucosa; droplet-size distribution is verified by laser diffraction under ISO 13320-1. Filling line speed is constrained by the same powder flow and moisture challenges described for oral solid dosage. The powder must not be exposed to ambient conditions above 25% RH for more than 30 minutes during transfer from the lyophiliser to the powder filler; otherwise cohesive bridging in the dosing auger causes fill weight drift. The fill line operates under dry nitrogen bleed in a low-humidity isolator.

Reconstituted solution hold time is a critical boundary. Without stabilising buffers, bacterial viability declines after 2 hours at ambient hatchery temperatures; this limit is established by viability decay studies rather than a universal standard. The reconstituted solution is not filtered, and the spray equipment is sanitised with non-residual hydrogen peroxide vapour rather than chlorine-based disinfectants. Published data for this specific Bordetella avium aerial spray configuration is limited, so hatchery validation includes settle plates and PCR swabbing of cabinet surfaces under the regional veterinary biologics inspection framework. The powder API is not compatible with standard carbohydrate fillers that caramelise at spray-cabinet heater settings; only cold-mist or low-temperature cabinet profiles are used. The final labelled product must state the approved reconstitution diluent, hold time, and environmental temperature limit.